Trial Search Results
Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in adolescents and adults with Epidermolysis Bullosa (EB).
Stanford is currently not accepting patients for this trial.
Jean Yuh Tang
Collaborator: Menlo Therapeutics Inc.
- Drug: VPD-737
- Other: Placebo
- Clinical diagnosis of epidermolysis bullosa and pruritus
- Have chronic liver or renal disease
Ages Eligible for Study
13 Years - N/A
Genders Eligible for Study